<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OTO</journal-id>
<journal-id journal-id-type="hwp">spoto</journal-id>
<journal-title>Otolaryngology–Head and Neck Surgery</journal-title>
<issn pub-type="ppub">0194-5998</issn>
<issn pub-type="epub">1097-6817</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0194599812471938</article-id>
<article-id pub-id-type="publisher-id">10.1177_0194599812471938</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Head and Neck Surgery</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Human Papilloma Virus Prevalence in a Multiethnic Screening Population</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Chen</surname><given-names>Kang Mei</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0194599812471938">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Stephen</surname><given-names>Josena K.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0194599812471938">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ghanem</surname><given-names>Tamer</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0194599812471938">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Stachler</surname><given-names>Robert</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0194599812471938">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gardner</surname><given-names>Glendon</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0194599812471938">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jones</surname><given-names>Lamont</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0194599812471938">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Schweitzer</surname><given-names>Vanessa P.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0194599812471938">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hall</surname><given-names>Francis</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0194599812471938">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Divine</surname><given-names>George</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff2-0194599812471938">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Worsham</surname><given-names>Maria J.</given-names></name>
<degrees>PhD, FACMG</degrees>
<xref ref-type="aff" rid="aff1-0194599812471938">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0194599812471938">
<label>1</label>Department of Otolaryngology/Head and Neck Research, Henry Ford Hospital, Detroit, Michigan, USA</aff>
<aff id="aff2-0194599812471938">
<label>2</label>Department of Public Health Sciences, Henry Ford Hospital, Detroit, Michigan, USA</aff>
<author-notes>
<corresp id="corresp1-0194599812471938">Maria J. Worsham, PhD, FACMG, Director of Research, Department of Otolaryngology/Head and Neck Research Henry Ford Hospital, 1 Ford Place, 1D, Detroit, MI 48202, USA Email: <email>mworsha1@hfhs.org</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2013</year>
</pub-date>
<volume>148</volume>
<issue>3</issue>
<fpage>436</fpage>
<lpage>442</lpage>
<history>
<date date-type="received">
<day>22</day>
<month>8</month>
<year>2012</year>
</date>
<date date-type="rev-recd">
<day>12</day>
<month>11</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>11</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© American Academy of Otolaryngology—Head and Neck Surgery Foundation 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">Official journal of the American Academy of Otolaryngology–Head and Neck Surgery Foundation</copyright-holder>
</permissions>
<abstract>
<sec id="section1-0194599812471938">
<title>Objective</title>
<p>The goal was to determine the prevalence of high-risk HPV16 using saliva in a screening population in Detroit, Michigan.</p>
</sec>
<sec id="section2-0194599812471938">
<title>Materials and Methods</title>
<p>Real-time quantitative polymerase chain reaction was applied to detect HPV16 in saliva DNA from 349 screening subjects without head and neck cancer (HNC), 156 with HNC, and 19 controls. Cut points for human papilloma virus (HPV) positivity were &gt;0 and &gt;0.001 copy/cell. Proportions were compared between groups using exact χ<sup>2</sup> or Fisher exact tests (<italic>P</italic> &lt; .05).</p>
</sec>
<sec id="section3-0194599812471938">
<title>Results</title>
<p>At a cut point &gt;0, each group had an overall HPV prevalence of more than 5%, with a higher prevalence of 30.8% in the HNC patient group. At a cut point &gt;0.001, the prevalence was lower: 0% in the control, 1.2% in the screening, and 16.7% in the HNC group. In the latter, for both cut points, HPV prevalence was different across sites (&lt;0.001) and significantly higher in the oropharynx than larynx or site as other after Hochberg’s adjustment. At &gt;0, women in the screening group had a higher prevalence of HPV than did men (<italic>P</italic> = .010), and at &gt;0.001, the prevalence was higher for men in the HNC group than for women (<italic>P</italic> = .035). In the screening group, at &gt;0, only African Americans had a higher prevalence than Caucasian Americans (<italic>P</italic> = .025).</p>
</sec>
<sec id="section4-0194599812471938">
<title>Conclusions</title>
<p>In the screening group, a 6.9% and 1.2% screening rate was noted at cut points &gt;0 and &gt;0.001, respectively. The results provide data to inform public health considerations of the feasibility of saliva as a screening tool in at-risk populations with the long-term goal of prophylactic vaccination against oral HPV.</p>
</sec>
</abstract>
<kwd-group>
<kwd>saliva</kwd>
<kwd>tumor</kwd>
<kwd>head and neck cancer (HNC)</kwd>
<kwd>HPV positive</kwd>
<kwd>HPV negative</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>The human papilloma virus (HPV), especially the oncogenic types, is a causative agent for some head and neck squamous cell carcinoma (HNSCC)<sup><xref ref-type="bibr" rid="bibr1-0194599812471938">1</xref>,<xref ref-type="bibr" rid="bibr2-0194599812471938">2</xref></sup> and an independent risk factor for oropharyngeal HNSCC (OPSCC).<sup><xref ref-type="bibr" rid="bibr3-0194599812471938">3</xref><xref ref-type="bibr" rid="bibr4-0194599812471938"/>-<xref ref-type="bibr" rid="bibr5-0194599812471938">5</xref></sup> A recent meta-analysis of 5681 HNSCC<sup><xref ref-type="bibr" rid="bibr6-0194599812471938">6</xref></sup> patients found that the prevalence of HPV infection was significantly higher among patients with OPSCC (35.6%) than among those with oral (23.5%) or laryngeal (24.0%) SCC.<sup><xref ref-type="bibr" rid="bibr7-0194599812471938">7</xref></sup> HPV type 16 (HPV16) accounts for approximately 95% of the infections in these HNSCC subgroups.<sup><xref ref-type="bibr" rid="bibr8-0194599812471938">8</xref></sup>
</p>
<p>The clinical significance of HPV in HNSCC pathogenesis has been well documented for OPSCC. HPV positive OPSCC patients have improved survival and respond better to treatment than HPV negative OPSCC patients. Since 1984, an increase in the prevalence, incidence, and survival of OPSCC is attributed to HPV infection.<sup><xref ref-type="bibr" rid="bibr9-0194599812471938">9</xref></sup>
</p>
<p>The current focus of HPV prevention efforts has been in cervical cancer. However, with regard to the increased future burden of OPSCC, when compared with the cervical cancer burden, 9 Surveillance Epidemiology and End Results registries projected that by 2010, the annual incidence rate of OPSCC among men will have surpassed that for cervical cancers.<sup><xref ref-type="bibr" rid="bibr9-0194599812471938">9</xref></sup> There would be a 4.7% reduction in incidence rate of head and neck cancer (HNC) in the United States if oncogenic HPV infection could be prevented.<sup><xref ref-type="bibr" rid="bibr10-0194599812471938">10</xref></sup> Most HPV positive HNCs occur in the oropharyngeal site, where the cancer is diagnosed in the late stages.<sup><xref ref-type="bibr" rid="bibr11-0194599812471938">11</xref></sup> This is due to the difficulty in distinguishing early OPSCC from lymphoid tonsillar and base-of-tongue tissue. Saliva-based screening tests, similar to noninvasive pap smear screening performed in cervical cancers, could help with the early detection of OPSCC. According to Zhao et al,<sup><xref ref-type="bibr" rid="bibr12-0194599812471938">12</xref></sup> for optimal feasibility using saliva rinse screening of HPV for HNC, the prevalence should be 5% or higher in the population screened. The aim of our study was to determine the prevalence of high-risk HPV16 infection in a multiethnic screening population in Detroit, Michigan.</p>
<sec id="section5-0194599812471938" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="section6-0194599812471938">
<title>Cohort</title>
<p>The cohort of 524 subjects consisted of three groups: 349 screening subjects without HNC (HN screen), 156 HNC patients (<xref ref-type="table" rid="table1-0194599812471938"><bold>Table 1</bold></xref>), and 19 control subjects. Of the 156 HNC patients, 154 were squamous cell carcinoma (HNSCC) and 2 were non-HNSCC. Of the 154 HNSCC patients, 52 were oropharyngeal SCC (OPSCC) and 102 were non-OPSCC (larynx, 44; oral cavity [OC], 32; hypopharynx [HP], 6; and site as other [lip-external, nose maxilla, nasopharynx, sinonasal], 22; <xref ref-type="table" rid="table2-0194599812471938"><bold>Table 2</bold></xref>).</p>
<table-wrap id="table1-0194599812471938" position="float">
<label>Table 1.</label>
<caption>
<p>Cohort Demographic Characteristics</p>
</caption>
<graphic alternate-form-of="table1-0194599812471938" xlink:href="10.1177_0194599812471938-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th align="center" colspan="5">HPV Cut Point 0<hr/></th>
<th align="center" colspan="5">HPV Cut Point 0.001<hr/></th>
</tr>
<tr>
<th/>
<th/>
<th align="center" colspan="2">HPV Positive (&gt;0)<hr/></th>
<th align="center" colspan="2">HPV Negative (0)<hr/></th>
<th/>
<th align="center" colspan="2">HPV Positive (≥0.001)<hr/></th>
<th align="center" colspan="2">HPV Negative (&lt;0.001)<hr/></th>
<th/>
</tr>
<tr>
<th/>
<th align="center">Total</th>
<th align="center">n</th>
<th align="center">%</th>
<th align="center">n</th>
<th align="center">%</th>
<th align="center">
<italic>P</italic> Value</th>
<th align="center">n</th>
<th align="center">%</th>
<th align="center">n</th>
<th align="center">%</th>
<th align="center">
<italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="12">Overall prevalence</td>
</tr>
<tr>
<td> Controls</td>
<td>19</td>
<td>1</td>
<td>5.3</td>
<td>18</td>
<td>94.7</td>
<td>&lt;<bold>.001</bold></td>
<td>0</td>
<td>0</td>
<td>19</td>
<td>100</td>
<td>&lt;<bold>.001</bold></td>
</tr>
<tr>
<td>  HN patients</td>
<td>156</td>
<td>48</td>
<td>30.8</td>
<td>108</td>
<td>69.2</td>
<td/>
<td>26</td>
<td>16.7</td>
<td>130</td>
<td>83.3</td>
<td/>
</tr>
<tr>
<td>  HN screen</td>
<td>349</td>
<td>24</td>
<td>6.9</td>
<td>325</td>
<td>93.1</td>
<td/>
<td>4</td>
<td>1.2</td>
<td>345</td>
<td>98.9</td>
<td/>
</tr>
<tr>
<td colspan="12">Prevalence by group and gender<sup><xref ref-type="table-fn" rid="table-fn2-0194599812471938">a</xref></sup>
</td>
</tr>
<tr>
<td colspan="12"> Controls</td>
</tr>
<tr>
<td>  Male</td>
<td>8</td>
<td>0</td>
<td>0</td>
<td>8</td>
<td>100</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>8</td>
<td>100</td>
<td>—</td>
</tr>
<tr>
<td>  Female</td>
<td>11</td>
<td>1</td>
<td>9.1</td>
<td>10</td>
<td>90.9</td>
<td/>
<td>0</td>
<td>0</td>
<td>11</td>
<td>100</td>
<td/>
</tr>
<tr>
<td colspan="12"> HN patients</td>
</tr>
<tr>
<td>  Male</td>
<td>119</td>
<td>40</td>
<td>33.6</td>
<td>79</td>
<td>66.4</td>
<td>.168</td>
<td>24</td>
<td>20.2</td>
<td>95</td>
<td>79.8</td>
<td>
<bold>.035</bold>
</td>
</tr>
<tr>
<td>  Female</td>
<td>37</td>
<td>8</td>
<td>21.6</td>
<td>29</td>
<td>78.4</td>
<td/>
<td>2</td>
<td>5.4</td>
<td>35</td>
<td>94.6</td>
<td/>
</tr>
<tr>
<td colspan="12"> HN screen</td>
</tr>
<tr>
<td>  Male</td>
<td>114</td>
<td>2</td>
<td>1.8</td>
<td>112</td>
<td>98.3</td>
<td>
<bold>.01</bold>
</td>
<td>1</td>
<td>0.9</td>
<td>113</td>
<td>99.1</td>
<td>1</td>
</tr>
<tr>
<td>  Female</td>
<td>224</td>
<td>21</td>
<td>9.4</td>
<td>203</td>
<td>90.6</td>
<td/>
<td>3</td>
<td>1.3</td>
<td>221</td>
<td>98.7</td>
<td/>
</tr>
<tr>
<td colspan="12">Prevalence by group and race<sup><xref ref-type="table-fn" rid="table-fn2-0194599812471938">a</xref></sup>
</td>
</tr>
<tr>
<td colspan="12"> Controls</td>
</tr>
<tr>
<td>  AA</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>100</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>100</td>
<td>—</td>
</tr>
<tr>
<td>  CA</td>
<td>7</td>
<td>0</td>
<td>0</td>
<td>7</td>
<td>100</td>
<td/>
<td>0</td>
<td>0</td>
<td>7</td>
<td>100</td>
<td/>
</tr>
<tr>
<td>  Other</td>
<td>11</td>
<td>1</td>
<td>9.1</td>
<td>10</td>
<td>90.9</td>
<td/>
<td>0</td>
<td>0</td>
<td>11</td>
<td>100</td>
<td/>
</tr>
<tr>
<td colspan="12"> HN patients</td>
</tr>
<tr>
<td>  AA</td>
<td>36</td>
<td>8</td>
<td>22.2</td>
<td>28</td>
<td>77.8</td>
<td>.410</td>
<td>3</td>
<td>8.3</td>
<td>33</td>
<td>91.7</td>
<td>.153</td>
</tr>
<tr>
<td>  CA</td>
<td>107</td>
<td>35</td>
<td>32.7</td>
<td>72</td>
<td>67.3</td>
<td/>
<td>19</td>
<td>17.8</td>
<td>88</td>
<td>82.2</td>
<td/>
</tr>
<tr>
<td>  Other</td>
<td>13</td>
<td>5</td>
<td>38.5</td>
<td>8</td>
<td>61.5</td>
<td/>
<td>4</td>
<td>30.8</td>
<td>9</td>
<td>69.2</td>
<td/>
</tr>
<tr>
<td colspan="12"> HN screen<sup><xref ref-type="table-fn" rid="table-fn3-0194599812471938">b</xref></sup>
</td>
</tr>
<tr>
<td>  AA</td>
<td>85</td>
<td>11</td>
<td>12.9</td>
<td>74</td>
<td>87.1</td>
<td>
<bold>.031</bold>
</td>
<td>3</td>
<td>3.5</td>
<td>82</td>
<td>96.5</td>
<td>.165</td>
</tr>
<tr>
<td>  CA</td>
<td>172</td>
<td>6</td>
<td>3.5</td>
<td>166</td>
<td>96.5</td>
<td/>
<td>1</td>
<td>0.6</td>
<td>171</td>
<td>99.4</td>
<td/>
</tr>
<tr>
<td>  Arab</td>
<td>57</td>
<td>5</td>
<td>8.8</td>
<td>52</td>
<td>91.2</td>
<td/>
<td>0</td>
<td>0</td>
<td>57</td>
<td>100</td>
<td/>
</tr>
<tr>
<td>  Other</td>
<td>26</td>
<td>1</td>
<td>3.9</td>
<td>25</td>
<td>96.2</td>
<td/>
<td>0</td>
<td>0</td>
<td>26</td>
<td>100</td>
<td/>
</tr>
<tr>
<td colspan="12">Prevalence by group and smoking<sup><xref ref-type="table-fn" rid="table-fn2-0194599812471938">a</xref></sup>
</td>
</tr>
<tr>
<td colspan="12"> Controls</td>
</tr>
<tr>
<td>  No</td>
<td>14</td>
<td>1</td>
<td>7.1</td>
<td>13</td>
<td>92.9</td>
<td>—</td>
<td>0</td>
<td>0</td>
<td>14</td>
<td>100</td>
<td>—</td>
</tr>
<tr>
<td>  Yes</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td/>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td/>
</tr>
<tr>
<td colspan="12"> HN patients</td>
</tr>
<tr>
<td>  No</td>
<td>76</td>
<td>29</td>
<td>38.2</td>
<td>47</td>
<td>61.8</td>
<td>.03</td>
<td>17</td>
<td>22.4</td>
<td>59</td>
<td>77.6</td>
<td>
<bold>.045</bold>
</td>
</tr>
<tr>
<td>  Yes</td>
<td>77</td>
<td>17</td>
<td>22.1</td>
<td>60</td>
<td>77.9</td>
<td/>
<td>8</td>
<td>10.4</td>
<td>69</td>
<td>89.6</td>
<td/>
</tr>
<tr>
<td colspan="12"> HN screen</td>
</tr>
<tr>
<td>  No</td>
<td>242</td>
<td>16</td>
<td>6.6</td>
<td>226</td>
<td>93.4</td>
<td>1</td>
<td>3</td>
<td>1.2</td>
<td>239</td>
<td>98.8</td>
<td>1</td>
</tr>
<tr>
<td>  Yes</td>
<td>81</td>
<td>6</td>
<td>7.4</td>
<td>75</td>
<td>92.6</td>
<td/>
<td>1</td>
<td>1.2</td>
<td>80</td>
<td>98.8</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0194599812471938">
<p>Abbreviations: AA, African American; CA, Caucasian American; HN, head and neck; HPV, human papilloma virus.</p>
</fn>
<fn id="table-fn2-0194599812471938">
<label>a</label>
<p>Missing; gender: 11 in HN screen; race: 9 in HN screen; smoking: 5 in controls, 3 in HN patients, 26 in HN screen.</p>
</fn>
<fn id="table-fn3-0194599812471938">
<label>b</label>
<p>After Hochberg’s adjustment of pairwise race comparisons of race groups, only AA had higher HPV prevalence than CA (<italic>P</italic> = .025).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0194599812471938" position="float">
<label>Table 2.</label>
<caption>
<p>HPV Prevalence in the HNC Group by Sites</p>
</caption>
<graphic alternate-form-of="table2-0194599812471938" xlink:href="10.1177_0194599812471938-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th align="center" colspan="5">HPV Cut Point 0<hr/></th>
<th align="center" colspan="5">HPV Cut Point 0.001<hr/></th>
</tr>
<tr>
<th/>
<th/>
<th align="center" colspan="2">HPV Positive (&gt;0), n = 48<hr/></th>
<th align="center" colspan="2">HPV Negative (0), n = 108<hr/></th>
<th/>
<th align="center" colspan="2">HPV Positive (≥0.001), n = 25<hr/></th>
<th align="center" colspan="2">HPV Negative (&lt;0.001), n = 131<hr/></th>
<th/>
</tr>
<tr>
<th align="left">Site</th>
<th align="center">Total</th>
<th align="center">n</th>
<th align="center">%</th>
<th align="center">n</th>
<th align="center">%</th>
<th align="center">
<italic>P</italic> Value</th>
<th align="center">n</th>
<th align="center">%</th>
<th align="center">n</th>
<th align="center">%</th>
<th align="center">
<italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>OP</td>
<td>52</td>
<td>28</td>
<td>58.3</td>
<td>24</td>
<td>22.2</td>
<td>&lt;<bold>.001</bold></td>
<td>19</td>
<td>36.5</td>
<td>33</td>
<td>63.5</td>
<td>&lt;<bold>.001</bold></td>
</tr>
<tr>
<td>Non-OP</td>
<td>104</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>OC</td>
<td>32</td>
<td>10</td>
<td>20.8</td>
<td>22</td>
<td>20.4</td>
<td/>
<td>5</td>
<td>15.6</td>
<td>27</td>
<td>84.4</td>
<td/>
</tr>
<tr>
<td>Larynx</td>
<td>44</td>
<td>4</td>
<td>8.3</td>
<td>40</td>
<td>37.0</td>
<td/>
<td>1</td>
<td>2.3</td>
<td>43</td>
<td>97.7</td>
<td/>
</tr>
<tr>
<td>HP</td>
<td>6</td>
<td>2</td>
<td>4.2</td>
<td>4</td>
<td>3.7</td>
<td/>
<td>0</td>
<td/>
<td>6</td>
<td>100</td>
<td/>
</tr>
<tr>
<td>Other</td>
<td>22</td>
<td>4</td>
<td>8.3</td>
<td>18</td>
<td>16.7</td>
<td/>
<td>0</td>
<td/>
<td>22</td>
<td>16.8</td>
<td/>
</tr>
<tr>
<td>HNSCC</td>
<td>20</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>Non-HNSCC</td>
<td>2</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0194599812471938">
<p>Abbreviations: HNC, head and neck cancer; HNSCC, head and neck squamous cell carcinoma; HP, hypopharynx; HPV, human papilloma virus; OC, oral cavity; OP, oropharynx; Other, lip-external, nose, maxilla, nasopharynx, sinonasal.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Saliva from the screening population was collected over a period of 4 years during 1-day screenings of participants in the Ear Nose &amp; Throat (ENT) clinic during Oral, Head and Neck Cancer Awareness Week, held every April, and a 2011 Health Fair at the Arab Community Center for Economic &amp; Social Services (ACCESS; Dearborn, Michigan). The 19 control subjects were ENT clinic and laboratory staff volunteers. Sexual behaviors of cohort subjects were not collected for this study.</p>
<p>This study was approved by the Henry Ford Health System Institutional Review Board committee, and informed consent was obtained from all enrolled subjects.</p>
</sec>
<sec id="section7-0194599812471938">
<title>DNA Extraction</title>
<p>Two milliliters of saliva was collected from each study subject in Oragene DNA kits (DNA Genotek Inc, Ontario, Canada), and saliva DNA was extracted according to the manufacturer’s instructions.</p>
</sec>
<sec id="section8-0194599812471938">
<title>HPV16 Detection by Quantitative Polymerase Chain Reaction</title>
<p>Tumor HPV DNA concentrations were measured using a real-time quantitative polymerase chain reaction (qPCR) system. Real-time PCR reactions were set up in a reaction volume of 20 µL using the TaqMan Universal Master Mix II with UNG (Applied Biosystems, Foster City, California). Specific primers and probes were designed to amplify a housekeeping gene, β<italic>-globin</italic>
<sup><xref ref-type="bibr" rid="bibr13-0194599812471938">13</xref></sup> (to standardize the input DNA), and the E6 region of HPV16<sup><xref ref-type="bibr" rid="bibr14-0194599812471938">14</xref></sup> as previously described.<sup><xref ref-type="bibr" rid="bibr15-0194599812471938">15</xref></sup> DNA amplifications were carried out in a 96-well reaction plate format in an Applied Biosystems 7900HT Sequence Detector. Multiple water blanks were included in every run. Both the HPV and β<italic>-globin</italic> PCR reactions were carried out in duplicate.</p>
<p>To determine HPV16 viral copy number, CaSki cell line (American Type Culture Collection, Manassas, Virginia) genomic DNA, known to have 600 copies/genome equivalent (6.6 pg of DNA/genome), was used to develop standard curves using serial dilutions of 50 ng, 5 ng, 0.5 ng, 0.05 ng, and 0.005 ng of DNA. Standard curves were also developed for the β<italic>-globin</italic> housekeeping gene (2 copies/genome) using the same serial dilutions. This allowed for relative quantification of the input DNA level and attribution of the final quantity as the number of viral copies/genome/cell.<sup><xref ref-type="bibr" rid="bibr16-0194599812471938">16</xref></sup>
</p>
</sec>
<sec id="section9-0194599812471938">
<title>Statistical Analysis</title>
<p>All data were analyzed using SAS 9.2. For prevalence, two cut points for HPV positivity were used: &gt;0 and &gt;0.001 copy/cell. Proportions were compared between groups using exact χ<sup>2</sup> or Fisher exact tests as appropriate based on expected cell count. Hochberg’s method was used to adjust for multiple comparisons.<sup><xref ref-type="bibr" rid="bibr17-0194599812471938">17</xref></sup> Statistical significance was set at <italic>P</italic> &lt; .05.</p>
</sec>
</sec>
<sec id="section10-0194599812471938" sec-type="results">
<title>Results</title>
<p>Oncogenic HPV16 was examined in saliva from 349 screening subjects without HNC (HN screen; African American [AA], 85; Caucasian American [CA], 172; Arab American, 57; other, 26; missing race, 9); 156 HNC patients (HN patient; AA, 36; CA, 107; other, 13), and 19 control subjects (AA, 1; CA, 7; other, 11). Age of the cohort ranged from 19 to 89 years. Gender distribution was as follows: there were twice as many women as men (224 vs 114) in the HN screening group, 3 times as many men as women (119 vs 37) in the HN patient group, and about equal numbers of men and women (8 vs 11) in the control group.</p>
<p>The overall prevalence of HPV was significantly different between the 3 groups (<italic>P</italic> &lt; .001) regardless of cut points (<xref ref-type="table" rid="table1-0194599812471938"><bold>Table 1</bold></xref>). At cut point &gt;0, the prevalence of HPV in the control, HN screen, and HN patient groups was 5.3%, 6.9%, and 30.8%, respectively. At cut point &gt;0.001, the prevalence was lower in each group: 0% in the control, 1.2% in the HN screen, and 16.7% in the HN patient group. For prevalence by group and gender (<xref ref-type="table" rid="table1-0194599812471938"><bold>Table 1</bold></xref>), women in the HN screen group had a higher prevalence of HPV than men (<italic>P</italic> = .01) at cut point &gt;0 only. At cut point &gt;0.001, the prevalence was higher for men in the HN patient group than women (<italic>P</italic> = .035).</p>
<p>Prevalence of HPV by race (<xref ref-type="table" rid="table1-0194599812471938"><bold>Table 1</bold></xref>) was significantly different in the screening group (<italic>P</italic> = .031) only at cut point &gt;0. Pairwise race comparisons in this group indicated that only AA had higher prevalence than CA (<italic>P</italic> = .025). In the HN patient group, more CA were HPV positive than AA (33% vs 22% at cut point &gt;0 and 18% vs 8% at cut point &gt;0.001), but this was not significant. HN patients who smoked were significantly less likely to be HPV positive (<italic>P</italic> = .03, cut point &gt;0; <italic>P</italic> = .045, cut point &gt;0.001; <xref ref-type="table" rid="table1-0194599812471938"><bold>Table 1</bold></xref>).</p>
<p>Within the HNC group, HPV prevalence was statistically significantly different (<italic>P</italic> &lt; .001) across sites for both cut points (<xref ref-type="table" rid="table2-0194599812471938"><bold>Table 2</bold></xref>). Pairwise comparisons for each site combination after Hochberg’s adjustment (<xref ref-type="table" rid="table3-0194599812471938"><bold>Table 3</bold></xref>) for both cut points indicated significantly higher HPV prevalence for oropharynx (OP) versus larynx (<italic>P</italic> &lt; .0001) and OP versus other (<italic>P</italic> = .0046 at cut point &gt;0 and <italic>P</italic> = .001 at cut point &gt;0.001). At cut point &gt;0.001, HPV prevalence in the larynx was significantly higher than in the oral cavity after Hochberg’s adjustment (<xref ref-type="table" rid="table3-0194599812471938"><bold>Table 3</bold></xref>).</p>
<table-wrap id="table3-0194599812471938" position="float">
<label>Table 3.</label>
<caption>
<p>Multiple Comparisons by Site within the HNC Group</p>
</caption>
<graphic alternate-form-of="table3-0194599812471938" xlink:href="10.1177_0194599812471938-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Site</th>
<th align="center">HPV Cut Point &gt;0, <italic>P</italic> Value</th>
<th align="center">HPV Cut Point &gt;0.001, <italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Larynx vs HP</td>
<td>.1457</td>
<td>1</td>
</tr>
<tr>
<td>Larynx vs OC</td>
<td>.0139</td>
<td>
<bold>.0770</bold>
<sup><xref ref-type="table-fn" rid="table-fn6-0194599812471938">a</xref></sup>
</td>
</tr>
<tr>
<td>Larynx vs OP</td>
<td>&lt;<bold>.0001</bold>
<sup><xref ref-type="table-fn" rid="table-fn6-0194599812471938">a</xref></sup>
</td>
<td>&lt;<bold>.0001</bold><sup><xref ref-type="table-fn" rid="table-fn6-0194599812471938">a</xref></sup></td>
</tr>
<tr>
<td>Larynx vs Other</td>
<td>.4249</td>
<td>1</td>
</tr>
<tr>
<td>HP vs OC</td>
<td>1</td>
<td>.5701</td>
</tr>
<tr>
<td>HP vs OP</td>
<td>.4155</td>
<td>.1634</td>
</tr>
<tr>
<td>HP vs other</td>
<td>.5806</td>
<td>—</td>
</tr>
<tr>
<td>OC vs OP</td>
<td>.0433</td>
<td>.0394</td>
</tr>
<tr>
<td>OC vs other</td>
<td>.2816</td>
<td>.072</td>
</tr>
<tr>
<td>OP vs other</td>
<td>
<bold>.0046</bold>
<sup><xref ref-type="table-fn" rid="table-fn6-0194599812471938">a</xref></sup>
</td>
<td>
<bold>.0010</bold>
<sup><xref ref-type="table-fn" rid="table-fn6-0194599812471938">a</xref></sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0194599812471938">
<p>Abbreviations: HP, hypopharynx; HPV, human papilloma virus; OC, oral cavity; OP, oropharynx; Other, lip-external, nose maxilla, nasopharynx, sinonasal.</p>
</fn>
<fn id="table-fn6-0194599812471938">
<label>a</label>
<p>Significant after Hochberg’s adjustment.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section11-0194599812471938" sec-type="discussion">
<title>Discussion</title>
<p>In the United States, approximately 52,610 new cases of HNC are expected in 2012, with an estimated 11,500 deaths from cancers of the oral cavity, pharynx, and larynx.<sup><xref ref-type="bibr" rid="bibr18-0194599812471938">18</xref></sup> In recent years, the incidence of HNC has been decreasing in United States due to a decrease in tobacco use.<sup><xref ref-type="bibr" rid="bibr19-0194599812471938">19</xref></sup> However, the incidence of HPV-related OPSCC has been rising.<sup><xref ref-type="bibr" rid="bibr9-0194599812471938">9</xref></sup> Despite considerable efforts, the 5-year survival rate for HNSCC has not changed significantly. Our goal was to determine the prevalence of high-risk HPV16 infection in the saliva of a screening population, consisting of control subjects, HN patients, and HN screening subjects without HNC, in Detroit, Michigan.</p>
<p>Regardless of study cut points, the overall prevalence of HPV was significantly different among the 3 groups (<italic>P</italic> &lt; .001). The overall HPV prevalence was more than 5% in each of the 3 groups at cut point &gt;0. At cut point &gt;0 and &gt;0.001, the HPV prevalence was significantly higher in the HN patient (30.8% and 16.7%, respectively) as compared with the HN screening group (6.9% and 1.2%, respectively). This higher prevalence in the saliva DNA from HN patients is supported by similar studies using comparable cut points.<sup><xref ref-type="bibr" rid="bibr12-0194599812471938">12</xref></sup> From a community screening study for HNSCC of 92 HN tumor and paired saliva rinse samples and saliva rinse from 604 control subjects, HPV prevalence by qPCR at cut point &gt;0 was 45.6% (42/92) in HNSCC patients. In the screening sample, HPV was detected in 2.8% and 1.3% of samples at cut points &gt;0 and &gt;0.001, respectively. The study measured sensitivity and specificity using cut points of &gt;0, &gt;0.001, and &gt;0.1 copies of HPV and determined a prevalence requirement of 5% or greater to achieve a positive predictive value close to 70%. A limitation of our study is the lack of HPV data on paired tumor and saliva rinse of the HN patient samples. Although our study achieved a prevalence rate of 6.9% at cut point &gt;0, at cut point &gt;0.001 the prevalence decreased to 1.2% in the screening sample. The study also lacked evaluation in the context of sensitivity and specificity (as well as the positive and negative predictive value) to more comprehensively make a case to argue in favor of saliva screening.</p>
<p>The multiethnic screening population in this study consisted of AA, CA, Arab American, and other. This is the first study to have an Arab American screening component. Of the 57 Arab Americans in the screening population, 5 were HPV positive (8.8%) and 52 were HPV negative at cut point &gt;0, but at cut point &gt;0.001, none remained HPV positive. With respect to race, HPV prevalence was significantly different among the 4 ethnic groups only for the HN screen group and at cut point &gt;0 only. Pairwise race comparisons demonstrated that at this cut point, AA had a higher HPV prevalence when compared with CA (12.9% vs 3.5%; <italic>P</italic> = .025). In the Gillison et al<sup><xref ref-type="bibr" rid="bibr20-0194599812471938">20</xref></sup> study of 5579 screening oral rinse samples from the 2009-2010 National Health and Nutrition Examination Survey (NHANES), a higher HPV prevalence in AA compared with CA was observed; however, this difference did not reach statistical significance. It is important to note that they detected HPV by multiplex PCR using primer pools followed by line-blot hybridization, which is not as sensitive as qPCR and can result in cross-contamination. For years ranging between 1984 and 2004, HPV positive patients were more likely to be younger, male, and CA or other races.<sup><xref ref-type="bibr" rid="bibr9-0194599812471938">9</xref></sup> Data from our prospective study as well as the recent rise in incidence of HPV-related OPSCC appear to support an increase in HPV incidence in the AA population as well.</p>
<p>There were twice as many women in the screening group as men, likely contributing to the higher prevalence of HPV positive women (at cut point &gt;0 only). This may reflect a better response to health care screening on the part of women. Turner et al<sup><xref ref-type="bibr" rid="bibr21-0194599812471938">21</xref></sup> demonstrated at cutoff &gt;0.001 a higher prevalence of HPV in nonwhite Hispanic women. Their study of 151 healthy adults had a roughly equal distribution of women and men (52.3% and 47.7%, respectively). The Gillison et al<sup><xref ref-type="bibr" rid="bibr20-0194599812471938">20</xref></sup> NHANES study reported a 5-fold higher prevalence of HPV16 in men over women. This increased prevalence is consistent with higher rates of HPV positive OPSCC in men. The latter observation is supported by data from our study, which show that at cut point &gt;0.001 in the HN patient group, more men than women were HPV positive (20.2% vs 5.4%, respectively; <italic>P</italic> = .035). Within the HNC group, HPV prevalence was significantly different across sites (larynx, OC, OP, HP, other), with the highest prevalence for the OP site versus larynx and OP versus other, regardless of cut points and after multiple comparisons.</p>
<p>The recognition of HPV as an etiologic agent for development of OPSCC, in addition to smoking and heavy alcohol consumption, likely reflects the rise in OPSCC in the United States and internationally,<sup><xref ref-type="bibr" rid="bibr22-0194599812471938">22</xref>,<xref ref-type="bibr" rid="bibr23-0194599812471938">23</xref></sup> despite a decrease in tobacco use in recent years. HPV may also be the primary oncogenic factor inducing carcinogenesis in patients without a history of tobacco or alcohol use. Non–tobacco and non–alcohol related OPSCC patients are 6 times more likely to harbor HPV than case-matched controls.<sup><xref ref-type="bibr" rid="bibr24-0194599812471938">24</xref></sup> In our study, we found a higher HPV positive rate in nonsmokers compared with smokers (38.2% vs 22.1%, <italic>P</italic> = .03, cut point &gt;0 and 22.4% vs 10.4%, <italic>P</italic> = .045, cut point &gt;0.001) in the HN patient group. The latter concurs with other studies where HPV is regarded as the main etiologic agent for OPSCC nonsmokers.<sup><xref ref-type="bibr" rid="bibr12-0194599812471938">12</xref>,<xref ref-type="bibr" rid="bibr24-0194599812471938">24</xref></sup>
</p>
<p>Also, HPV prevalence remained higher in the larynx when compared with the oral cavity at cut point &gt;0.001 after pairwise site adjustment. Laryngeal squamous cell cancer (LSCC), the largest subgroup of head and neck cancers, share common risk factors, including smoking and alcohol consumption. The prevalence of oncogenic HPV types in LSCC has a wide distribution, ranging from 0%<sup><xref ref-type="bibr" rid="bibr25-0194599812471938">25</xref></sup> to 69%,<sup><xref ref-type="bibr" rid="bibr26-0194599812471938">26</xref></sup> attributable mainly to differences in methods of HPV detection as well as selection bias due to small sample size or the poor quality of cancer specimen.<sup><xref ref-type="bibr" rid="bibr27-0194599812471938">27</xref></sup> In a pooled meta-analysis<sup><xref ref-type="bibr" rid="bibr7-0194599812471938">7</xref></sup> using conventional PCR-based assays, the prevalence of HPV16 in LSCC was 17%.<sup><xref ref-type="bibr" rid="bibr7-0194599812471938">7</xref></sup> In a recent study, HPV16, detected by real-time qPCR, had a reported prevalence of 27%, supporting a role for HPV in LSCC.<sup><xref ref-type="bibr" rid="bibr28-0194599812471938">28</xref></sup>
</p>
<p>HPV prevalence and its detection in saliva DNA in the screening population is of high clinical significance because of HPV’s recognition as a causative agent for some HNSCC. Paradoxically, HPV positive HNSCC patients, particularly OPSCC patients, show improved survival,<sup><xref ref-type="bibr" rid="bibr3-0194599812471938">3</xref></sup> due in part to a better response to chemoradation.<sup><xref ref-type="bibr" rid="bibr29-0194599812471938">29</xref></sup> In addition to studies reporting improved survival in HPV positive OPSCC never smokers,<sup><xref ref-type="bibr" rid="bibr30-0194599812471938">30</xref></sup> recent studies show that HPV positive OPSCC smokers had improved prognostic outcomes when compared with HPV negative OPSCC smokers.<sup><xref ref-type="bibr" rid="bibr31-0194599812471938">31</xref></sup> The latter points to a putative role of HPV as a modulator of the malignancy process in smoking and alcohol related OPSCC.<sup><xref ref-type="bibr" rid="bibr21-0194599812471938">21</xref></sup>
</p>
<p>The main focus of prophylactic HPV vaccination has been on cervical cancers. This is justified as the public health burden of cervical precancer and invasive cancer is greater when compared with OPSCC. The incidence rates of cervical cancer would be greater if not for the current screening protocol that is in place.<sup><xref ref-type="bibr" rid="bibr9-0194599812471938">9</xref></sup> It is estimated that by 2020, the number of HPV positive OPSCC will surpass the number of cervical cancers.<sup><xref ref-type="bibr" rid="bibr20-0194599812471938">20</xref></sup> Considering the increasing incidence rates in OPSCC seen in recent years, it may be worthwhile to develop a screening process for early detection of these cancers. However, in the absence of a standardized evidence-based screening process, it may be useful to evaluate the efficacy of HPV vaccination in preventing oral HPV infection. The quadrivalent HPV vaccine has been determined to be highly efficacious in preventing extracervical infections in women<sup><xref ref-type="bibr" rid="bibr32-0194599812471938">32</xref></sup> and penile and anal infections<sup><xref ref-type="bibr" rid="bibr33-0194599812471938">33</xref>,<xref ref-type="bibr" rid="bibr34-0194599812471938">34</xref></sup> in men. HPV vaccination is already in place for young boys.<sup><xref ref-type="bibr" rid="bibr35-0194599812471938">35</xref></sup> Considering that most HPV positive OPSCC cases are in men, prophylactic HPV vaccination in adult males may be a consideration.</p>
<p>The higher prevalence of HPV in AA versus CA in the screening population in our study is difficult to interpret and necessitates additional investigation. Overall, the results of this study provide HPV prevalence data in understudied AA and Arab American screening groups. Pursuing the feasibility of saliva as a screening tool in higher-risk populations is relevant not only to early detection of HNC but also to the long-term goal of establishing a rationale for prophylactic vaccination against oral HPV acquisition. Currently, no screening process is available for oral HPV detection. A rationale to justify screening for oral HPV will require assessment of oral HPV prevalence in larger cohorts with sufficient representation of different ethnicities/races in the context of sensitivity and specificity, as well as clear recommendations of interventional strategies for individuals with oral HPV.</p>
</sec>
<sec id="section12-0194599812471938">
<title>Author Contributions</title>
<p>
<bold>Kang Mei Chen</bold>, (1) substantial contributions to conception and design, acquisition of data, analysis, and interpretation of data; (2) drafting the article and revising it critically for important intellectual content; and (3) final approval of the version to be published; <bold>Josena K. Stephen</bold>, (1) substantial contributions to conception and design, acquisition of data, and interpretation of data; (2) drafting the article and revising it critically for important intellectual content; and (3) final approval of the version to be published; <bold>Tamer Ghanem</bold>, (1) substantial contributions to conception and design, acquisition of data, and interpretation of data; (2) drafting the article and revising it critically for important intellectual content; and (3) final approval of the version to be published; <bold>Robert Stachler</bold>, (1) substantial contributions to conception and design, acquisition of data; (2) drafting the article and revising it critically for important intellectual content; and (3) final approval of the version to be published; <bold>Glendon Gardner</bold>, (1) substantial contributions to conception and design, acquisition of data; (2) drafting the article and revising it critically for important intellectual content; and (3) final approval of the version to be published; <bold>Lamont Jones</bold>, (1) substantial contributions to conception and design, acquisition of data; (2) drafting the article and revising it critically for important intellectual content; and (3) final approval of the version to be published; <bold>Vanessa P. Schweitzer</bold>, (1) substantial contributions to conception and design, acquisition of data; (2) drafting the article and revising it critically for important intellectual content; and (3) final approval of the version to be published; <bold>Francis Hall</bold>, (1) substantial contributions to conception and design, acquisition of data; (2) drafting the article and revising it critically for important intellectual content; and (3) final approval of the version to be published; <bold>George Divine</bold>, (1) substantial contributions to conception and design, acquisition of data, and analysis and interpretation of data; (2) drafting the article and revising it critically for important intellectual content; and (3) final approval of the version to be published; <bold>Maria J. Worsham</bold>, (1) substantial contributions to conception and design, acquisition of data, analysis, and interpretation of data; (2) drafting the article and revising it critically for important intellectual content; and (3) final approval of the version to be published.</p>
</sec>
<sec id="section13-0194599812471938">
<title>Disclosures</title>
<p>
<bold>Competing interests:</bold> Robert Stachler, Teva: consultant, advisory board, speaker’s bureau. This disclosure is not related to the article.</p>
<p>
<bold>Sponsorships:</bold> National Institutes of Health.</p>
<p>
<bold>Funding source</bold>: R01 DE15990.</p>
</sec>
</body>
<back>
<ack>
<p>Drs Alvin Ko, Werner Roennecke, Ahsan Syed, William Young, Syamal Mausumi, Brandon Musgrave, Robert Deeb; Dr Adnan Hammad and Mona Farroukh (ACCESS); and Wayne State University medical students (Paul Judge, Mathew Smithe, Mark Toma, Carmen Tugulan, Mark Shamoun, Usam Khalid, Haroon Yousul, Lisa Vitale, Hemancher Makker, Victoria Yee, Emin Elezi, Shawn Kumar) contributed to patient recruitment efforts and saliva collection. Meredith Mahan assisted with statistical data analysis. Dr Worsham had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p>
</ack>
<fn-group>
<fn fn-type="presented-at">
<p>Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.</p>
<p>This article was presented at the 2012 AAO-HNSF Annual Meeting and OTO EXPO; September 9-12, 2012; Washington, DC.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0194599812471938">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gillison</surname><given-names>ML</given-names></name>
<name><surname>Lowy</surname><given-names>DR</given-names></name>
</person-group>. <article-title>A causal role for human papillomavirus in head and neck cancer</article-title>. <source>Lancet</source>. <year>2004</year>;<volume>363</volume>:<fpage>1488</fpage>-<lpage>1489</lpage>.</citation>
</ref>
<ref id="bibr2-0194599812471938">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gillison</surname><given-names>ML</given-names></name>
<name><surname>Koch</surname><given-names>WM</given-names></name>
<name><surname>Capone</surname><given-names>RB</given-names></name>
<etal/>
</person-group>. <article-title>Evidence for a causal association between human papillomavirus and a subset of head and neck cancers</article-title>. <source>J Natl Cancer Inst</source>. <year>2000</year>;<volume>92</volume>:<fpage>709</fpage>-<lpage>720</lpage>.</citation>
</ref>
<ref id="bibr3-0194599812471938">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ang</surname><given-names>KK</given-names></name>
<name><surname>Harris</surname><given-names>J</given-names></name>
<name><surname>Wheeler</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Human papillomavirus and survival of patients with oropharyngeal cancer</article-title>. <source>N Engl J Med</source>. <year>2010</year>;<volume>363</volume>:<fpage>24</fpage>-<lpage>35</lpage>.</citation>
</ref>
<ref id="bibr4-0194599812471938">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>D’Souza</surname><given-names>G</given-names></name>
<name><surname>Kreimer</surname><given-names>AR</given-names></name>
<name><surname>Viscidi</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Case-control study of human papillomavirus and oropharyngeal cancer</article-title>. <source>N Engl J Med</source>. <year>2007</year>;<volume>356</volume>:<fpage>1944</fpage>-<lpage>1956</lpage>.</citation>
</ref>
<ref id="bibr5-0194599812471938">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>AA</given-names></name>
<name><surname>Marsit</surname><given-names>CJ</given-names></name>
<name><surname>Christensen</surname><given-names>BC</given-names></name>
<etal/>
</person-group>. <article-title>Genetic variation in the vitamin C transporter, SLC23A2, modifies the risk of HPV16-associated head and neck cancer</article-title>. <source>Carcinogenesis</source>. <year>2009</year>;<volume>30</volume>:<fpage>977</fpage>-<lpage>981</lpage>.</citation>
</ref>
<ref id="bibr6-0194599812471938">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dayyani</surname><given-names>F</given-names></name>
<name><surname>Etzel</surname><given-names>CJ</given-names></name>
<name><surname>Liu</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC)</article-title>. <source>Head Neck Oncol</source>. <year>2010</year>;<volume>2</volume>:<fpage>15</fpage>.</citation>
</ref>
<ref id="bibr7-0194599812471938">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kreimer</surname><given-names>AR</given-names></name>
<name><surname>Clifford</surname><given-names>GM</given-names></name>
<name><surname>Boyle</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source>. <year>2005</year>;<volume>14</volume>:<fpage>467</fpage>-<lpage>475</lpage>.</citation>
</ref>
<ref id="bibr8-0194599812471938">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gillison</surname><given-names>ML</given-names></name>
<name><surname>D’Souza</surname><given-names>G</given-names></name>
<name><surname>Westra</surname><given-names>W</given-names></name>
<etal/>
</person-group>. <article-title>Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers</article-title>. <source>J Natl Cancer Inst</source>. <year>2008</year>;<volume>100</volume>:<fpage>407</fpage>-<lpage>420</lpage>.</citation>
</ref>
<ref id="bibr9-0194599812471938">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chaturvedi</surname><given-names>AK</given-names></name>
<name><surname>Engels</surname><given-names>EA</given-names></name>
<name><surname>Pfeiffer</surname><given-names>RM</given-names></name>
<etal/>
</person-group>. <article-title>Human papillomavirus and rising oropharyngeal cancer incidence in the United States</article-title>. <source>J Clin Oncol</source>. <year>2011</year>;<volume>29</volume>:<fpage>4294</fpage>-<lpage>4301</lpage>.</citation>
</ref>
<ref id="bibr10-0194599812471938">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sanders</surname><given-names>AE</given-names></name>
<name><surname>Slade</surname><given-names>GD</given-names></name>
<name><surname>Patton</surname><given-names>LL</given-names></name>
</person-group>. <article-title>National prevalence of oral HPV infection and related risk factors in the U.S. adult population</article-title>. <source>Oral Dis</source>. <year>2012</year>;<volume>18</volume>:<fpage>430</fpage>-<lpage>441</lpage>.</citation>
</ref>
<ref id="bibr11-0194599812471938">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Forastiere</surname><given-names>A</given-names></name>
<name><surname>Koch</surname><given-names>W</given-names></name>
<name><surname>Trotti</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Head and neck cancer</article-title>. <source>N Engl J Med</source>. <year>2001</year>;<volume>345</volume>:<fpage>1890</fpage>-<lpage>1900</lpage>.</citation>
</ref>
<ref id="bibr12-0194599812471938">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>M</given-names></name>
<name><surname>Rosenbaum</surname><given-names>E</given-names></name>
<name><surname>Carvalho</surname><given-names>AL</given-names></name>
<etal/>
</person-group>. <article-title>Feasibility of quantitative PCR-based saliva rinse screening of HPV for head and neck cancer</article-title>. <source>Int J Cancer</source>. <year>2005</year>;<volume>117</volume>:<fpage>605</fpage>-<lpage>610</lpage>.</citation>
</ref>
<ref id="bibr13-0194599812471938">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lo</surname><given-names>YM</given-names></name>
<name><surname>Tein</surname><given-names>MS</given-names></name>
<name><surname>Lau</surname><given-names>TK</given-names></name>
<etal/>
</person-group>. <article-title>Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis</article-title>. <source>Am J Hum Genet</source>. <year>1998</year>;<volume>62</volume>:<fpage>768</fpage>-<lpage>775</lpage>.</citation>
</ref>
<ref id="bibr14-0194599812471938">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Peitsaro</surname><given-names>P</given-names></name>
<name><surname>Johansson</surname><given-names>B</given-names></name>
<name><surname>Syrjanen</surname><given-names>S</given-names></name>
</person-group>. <article-title>Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique</article-title>. <source>J Clin Microbiol</source>. <year>2002</year>;<volume>40</volume>:<fpage>886</fpage>-<lpage>891</lpage>.</citation>
</ref>
<ref id="bibr15-0194599812471938">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stephen</surname><given-names>JK</given-names></name>
<name><surname>Chen</surname><given-names>KM</given-names></name>
<name><surname>Shah</surname><given-names>V</given-names></name>
<etal/>
</person-group>. <article-title>Human papillomavirus outcomes in an access-to-care laryngeal cancer cohort</article-title>. <source>Otolaryngol Head Neck Surg</source>. <year>2012</year>;<volume>146</volume>:<fpage>730</fpage>-<lpage>738</lpage>.</citation>
</ref>
<ref id="bibr16-0194599812471938">
<label>16.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Perkin-Elmer</surname></name>
</person-group>. <source>User Bulletin #2: ABI Prism 7700 Sequence Detection System</source>. <publisher-loc>Foster City, CA</publisher-loc>: <publisher-name>Perkin-Elmer Corporation</publisher-name>; <year>1997</year>.</citation>
</ref>
<ref id="bibr17-0194599812471938">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hochberg</surname><given-names>Y</given-names></name>
<name><surname>Benjamini</surname><given-names>Y</given-names></name>
</person-group>. <article-title>More powerful procedures for multiple significance testing</article-title>. <source>Stat Med</source>. <year>1990</year>;<volume>9</volume>:<fpage>811</fpage>-<lpage>818</lpage>.</citation>
</ref>
<ref id="bibr18-0194599812471938">
<label>18.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Society</surname><given-names>AC</given-names></name>
</person-group>. <source>Cancer Facts &amp; Figures 2012</source>. <publisher-loc>Atlanta, GA</publisher-loc>: <publisher-name>American Cancer Society</publisher-name>; <year>2012</year>.</citation>
</ref>
<ref id="bibr19-0194599812471938">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marur</surname><given-names>S</given-names></name>
<name><surname>D’Souza</surname><given-names>G</given-names></name>
<name><surname>Westra</surname><given-names>WH</given-names></name>
<etal/>
</person-group>. <article-title>HPV-associated head and neck cancer: a virus-related cancer epidemic</article-title>. <source>Lancet Oncol</source>. <year>2010</year>;<volume>11</volume>:<fpage>781</fpage>-<lpage>789</lpage>.</citation>
</ref>
<ref id="bibr20-0194599812471938">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gillison</surname><given-names>ML</given-names></name>
<name><surname>Broutian</surname><given-names>T</given-names></name>
<name><surname>Pickard</surname><given-names>RK</given-names></name>
<etal/>
</person-group>. <article-title>Prevalence of oral HPV infection in the United States, 2009-2010</article-title>. <source>JAMA</source>. <year>2012</year>;<volume>307</volume>:<fpage>693</fpage>-<lpage>703</lpage>.</citation>
</ref>
<ref id="bibr21-0194599812471938">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Turner</surname><given-names>DO</given-names></name>
<name><surname>Williams-Cocks</surname><given-names>SJ</given-names></name>
<name><surname>Bullen</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>High-risk human papillomavirus (HPV) screening and detection in healthy patient saliva samples: a pilot study</article-title>. <source>BMC Oral Health</source>. <year>2011</year>;<volume>11</volume>:<fpage>28</fpage>.</citation>
</ref>
<ref id="bibr22-0194599812471938">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chaturvedi</surname><given-names>AK</given-names></name>
<name><surname>Engels</surname><given-names>EA</given-names></name>
<name><surname>Anderson</surname><given-names>WF</given-names></name>
<etal/>
</person-group>. <article-title>Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States</article-title>. <source>J Clin Oncol</source>. <year>2008</year>;<volume>26</volume>:<fpage>612</fpage>-<lpage>619</lpage>.</citation>
</ref>
<ref id="bibr23-0194599812471938">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ramqvist</surname><given-names>T</given-names></name>
<name><surname>Dalianis</surname><given-names>T</given-names></name>
</person-group>. <article-title>Oropharyngeal cancer epidemic and human papillomavirus</article-title>. <source>Emerg Infect Dis</source>. <year>2010</year>;<volume>16</volume>:<fpage>1671</fpage>-<lpage>1677</lpage>.</citation>
</ref>
<ref id="bibr24-0194599812471938">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Andrews</surname><given-names>E</given-names></name>
<name><surname>Seaman</surname><given-names>WT</given-names></name>
<name><surname>Webster-Cyriaque</surname><given-names>J</given-names></name>
</person-group>. <article-title>Oropharyngeal carcinoma in non-smokers and non-drinkers: a role for HPV</article-title>. <source>Oral Oncol</source>. <year>2009</year>;<volume>45</volume>:<fpage>486</fpage>-<lpage>491</lpage>.</citation>
</ref>
<ref id="bibr25-0194599812471938">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gallo</surname><given-names>A</given-names></name>
<name><surname>Degener</surname><given-names>AM</given-names></name>
<name><surname>Pagliuca</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Detection of human papillomavirus and adenovirus in benign and malignant lesions of the larynx</article-title>. <source>Otolaryngol Head Neck Surg</source>. <year>2009</year>;<volume>141</volume>:<fpage>276</fpage>-<lpage>281</lpage>.</citation>
</ref>
<ref id="bibr26-0194599812471938">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gallegos-Hernandez</surname><given-names>JF</given-names></name>
<name><surname>Paredes-Hernandez</surname><given-names>E</given-names></name>
<name><surname>Flores-Diaz</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Human papillomavirus: association with head and neck cancer</article-title>. <source>Cir Cir</source>. <year>2007</year>;<volume>75</volume>:<fpage>151</fpage>-<lpage>5</lpage>.</citation>
</ref>
<ref id="bibr27-0194599812471938">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Torrente</surname><given-names>MC</given-names></name>
<name><surname>Rodrigo</surname><given-names>JP</given-names></name>
<name><surname>Haigentz</surname><given-names>M</given-names><suffix>Jr</suffix></name>
<etal/>
</person-group>. <article-title>Human papillomavirus infections in laryngeal cancer</article-title>. <source>Head Neck</source>. <year>2011</year>;<volume>33</volume>:<fpage>581</fpage>-<lpage>586</lpage>.</citation>
</ref>
<ref id="bibr28-0194599812471938">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stephen</surname><given-names>JK</given-names></name>
<name><surname>Chen</surname><given-names>KM</given-names></name>
<name><surname>Shah</surname><given-names>V</given-names></name>
<etal/>
</person-group>. <article-title>Human papillomavirus outcomes in an access-to-care laryngeal cancer cohort</article-title>. <source>Otolaryngol Head Neck Surg</source>. <year>2012</year>;<volume>146</volume>:<fpage>730</fpage>-<lpage>738</lpage>.</citation>
</ref>
<ref id="bibr29-0194599812471938">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rischin</surname><given-names>D</given-names></name>
<name><surname>Young</surname><given-names>RJ</given-names></name>
<name><surname>Fisher</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial</article-title>. <source>J Clin Oncol</source>. <year>2010</year>;<volume>28</volume>:<fpage>4142</fpage>-<lpage>4148</lpage>.</citation>
</ref>
<ref id="bibr30-0194599812471938">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Maxwell</surname><given-names>JH</given-names></name>
<name><surname>Kumar</surname><given-names>B</given-names></name>
<name><surname>Feng</surname><given-names>FY</given-names></name>
<etal/>
</person-group>. <article-title>Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence</article-title>. <source>Clin Cancer Res</source>. <year>2010</year>;<volume>16</volume>:<fpage>1226</fpage>-<lpage>1235</lpage>.</citation>
</ref>
<ref id="bibr31-0194599812471938">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gillison</surname><given-names>ML</given-names></name>
<name><surname>Harris</surname><given-names>J</given-names></name>
<name><surname>Westra</surname><given-names>W</given-names></name>
<etal/>
</person-group>. <article-title>Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129</article-title>. <source>J Clin Oncol</source>. <year>2009</year>;<fpage>27</fpage>.</citation>
</ref>
<ref id="bibr32-0194599812471938">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Garland</surname><given-names>SM</given-names></name>
<name><surname>Hernandez-Avila</surname><given-names>M</given-names></name>
<name><surname>Wheeler</surname><given-names>CM</given-names></name>
<etal/>
</person-group>. <article-title>Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases</article-title>. <source>N Engl J Med</source>. <year>2007</year>;<volume>356</volume>:<fpage>1928</fpage>-<lpage>1943</lpage>.</citation>
</ref>
<ref id="bibr33-0194599812471938">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Giuliano</surname><given-names>AR</given-names></name>
<name><surname>Palefsky</surname><given-names>JM</given-names></name>
<name><surname>Goldstone</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males</article-title>. <source>N Engl J Med</source>. <year>2011</year>;<volume>364</volume>:<fpage>401</fpage>-<lpage>411</lpage>.</citation>
</ref>
<ref id="bibr34-0194599812471938">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Palefsky</surname><given-names>JM</given-names></name>
<name><surname>Giuliano</surname><given-names>AR</given-names></name>
<name><surname>Goldstone</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>HPV vaccine against anal HPV infection and anal intraepithelial neoplasia</article-title>. <source>N Engl J Med</source>. <year>2011</year>;<volume>365</volume>:<fpage>1576</fpage>-<lpage>1585</lpage>.</citation>
</ref>
<ref id="bibr35-0194599812471938">
<label>35.</label>
<citation citation-type="journal">
<collab>Centers for Disease Prevention</collab>. <article-title>Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine in Males: Advisory Committee on Immunization Practices (ACIP)</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <year>2011</year>;<volume>60</volume>:<fpage>1705</fpage>-<lpage>1708</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>